Tianjin Medical University Cancer Institute and Hospital: Breast Neoplasms trials

The registry lists 52 Breast Neoplasms studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 30 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 22Phase 3 5Phase 4 1No phase 26(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hypofractionated Radiotherapy After Breast Reconstruction for Breast CancerNot yet recruitingNCT07831889Not applicable
• Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient AdherenceRecruitingNCT07817056
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingNCT07708194Phase 1/2
• Exploratory Study of SHR-A1811 Via Different Administration Routes in PatientsNot yet recruitingNCT07560475Phase 2
• A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast CancerNot yet recruitingNCT07441486Phase 2
• Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant ChemotherapyNot yet recruitingNCT07410234Phase 2
• Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor TherapyEnrolling by invitationNCT07409298Not applicable
• Real-world Studies of CDK4/6 InhibitorsRecruitingNCT07407439
• Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With ChemotherapyRecruitingNCT07372079Phase 2
• Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake StatusRecruitingNCT07350928Phase 3
• SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyNot yet recruitingNCT07307287Phase 2
• Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast CancerNot yet recruitingNCT07246317Phase 2
• Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer PatientsNot yet recruitingNCT07162519Not applicable
• Supermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb LymphedemaNot yet recruitingNCT07026292Not applicable
• Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07005583Phase 2
• A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast CancerRecruitingNCT06878625Phase 2
• Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic TherapyRecruitingNCT06498154Phase 2
• The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 PositiveNot yet recruitingNCT06495541Not applicable
• Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast CancerNot yet recruitingNCT06483386Phase 2
• Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity ResultsNot yet recruitingNCT06438055Not applicable
• A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line ChemotherapyRecruitingNCT05890287Not applicable
• Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI ResearchRecruitingNCT05885776Phase 2
• Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNot yet recruitingNCT05806671Phase 2
• A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR AlterationsRecruitingNCT05560334Phase 2
• Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyNot yet recruitingNCT05560308Not applicable
• A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast CancerRecruitingNCT04970264
• Breast Mesh Used in Two-staged Breast ReconstructionRecruitingNCT04967976Not applicable
• Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT04907344Phase 2/3
• Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerNot yet recruitingNCT04900311Phase 2
• Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast CancerRecruitingNCT02506361
• Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer PatientsCompletedNCT06009627Phase 2/3
• A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast CancerStatus unknownNCT05871918Phase 3
• Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at RiskCompletedNCT05787522
• The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.Status unknownNCT05781633Not applicable
• Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast CancerStatus unknownNCT05295043Not applicable
• H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World StudyStatus unknownNCT05167643Not applicable
• Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast CancerStatus unknownNCT05085626Phase 2
• Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast CancerCompletedNCT04903652Phase 2
• SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.CompletedNCT04836520Phase 2
• A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.Status unknownNCT04733417Phase 2
• Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and ChemotherapyStatus unknownNCT04582955Not applicable
• Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in ChinaStatus unknownNCT04526028
• Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.CompletedNCT03983096
• Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction PatientsStatus unknownNCT03742908Not applicable
• Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast CancerStatus unknownNCT03348098Phase 2
• Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer PatientsStatus unknownNCT02812277
• PERCIST Criteria for Response Evaluation With Solid TumorsStatus unknownNCT02765620
• Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast CancerStatus unknownNCT02207361Phase 4
• Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast CancerStatus unknownNCT02207335Phase 3
• Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast CancerStatus unknownNCT02161315
• Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast CancerStatus unknownNCT01635465
• The Diagnostic Technology Applied Research of CDK5RAP2 in Breast CancerStatus unknownNCT01634984